Lupin to boost complex generics in US, EU; eyes chronic growth in India
Lupin, which plans to develop the specialty business, is eyeing higher revenue share from its complex generics portfolios in the US and Europe. Moreover, with a pipeline of over 200…
Lupin receives US FDA Establishment Inspection Report for Somerset facility
Lupin has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its manufacturing facility in Somerset, New Jersey.…